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ABSTRACT We have sequenced the virulent Asibi strain
of yellow fever virus and compared this sequence to that of the
17D vaccine strain, which was derived from it. These two
strains of viruses differ by more than 240 passages. We found
that the two RNAs, 10,862 nucleotides long, differ at 68
nucleotide positions; these changes result in 32 amino acid
differences. Overall, this corresponds to 0.63% nucleotide
sequence divergence, and the changes are scattered throughout
the genome. The overall divergence at the level of amino acid
substitution is 0.94%, but these changes are not randomly
distributed among the virus proteins. The capsid protein is
unchanged, while proteins NS1, NS3, and NS5 contain 0.5%
amino acid substitutions, and proteins ns4a and ns4b average
0.8% substitutions. In contrast, proteins ns2a and ns2b have
3.0 and 2.3% amino acid divergence, respectively. The enve-
lope protein also has a relatively high rate ofamino acid change
of 2.4% (a total of 12 amino acid substitutions). The large
number of changes in ns2a and ns2b, which are largely
conservative in nature, may result from lowered selective
pressure against alteration in this region; among flaviviruses,
these polypeptides are much less highly conserved than NS1,
NS3, and NS5. However, many of the amino acid substitutions
in the E protein are not conservative. It seems likely that at least
some of the difference in virulence between the two strains of
yellow fever virus results from changes in the envelope protein
that affect virus binding to host receptors. Such differences in
receptor binding could result in the reduced neurotropism and
vicerotropism exhibited by the vaccine strain.
Yellow fever virus belongs to the Flavivirus genus of the
family Flaviviridae, a group of some 70 closely related
viruses many of which cause serious human illness (1).
Yellow fever is arthropod-borne, transmitted by mosquitos of
the genera Aedes and Haemagogus. Its natural vertebrate
host range is limited to primates in which it is viscerotropic
and neurotropic. In man, the virus causes a serious, often
fatal, illness marked by liver and kidney involvement and
hemorrhage. For several hundred years the virus caused
epidemics in the Americas, Europe, and Africa that led to
widespread human suffering. With the control of the urban
vector of yellow fever Aedes aegypti beginning in the early
1900s, epidemic urban yellow fever disappeared. However,
the virus remains present in an enzootic cycle in the forests
of South America and Africa and causes periodic outbreaks
in neighboring human populations.
Reed (2) first proved that yellow fever is transmitted by
mosquitos and, shortly thereafter, that the disease agent was
filterable. Because there was no recognized, susceptible
laboratory host, many years elapsed before the virus respon-
sible was isolated by the Rockefeller Foundation's West
Africa yellow fever commission. In 1927, these workers
succeeded in isolating a virus from the blood of a young
Ghanian named Asibi by monkey/monkey passage (3). This
Asibi strain of yellow fever causes an invariably fatal disease
when inoculated into rhesus monkeys.
Theiler (4) developed a live, attenuated vaccine strain,
which he referred to as 17D, from the Asibi strain. Starting
with the Asibi strain that had been passaged 53 times in
monkeys, with intermittent passages in A. aegypti, the virus
was propagated serially in cultures of embryonic mouse
tissue (18 passages), minced whole chicken embryo (50
passages), and finally minced chicken embryos without
nervous tissue (152 passages). Between the 89th and 114th in
vitro passage (from the start of the experiment, that is
including the passages in embryonic mouse tissue and whole
chicken embryos) a marked change in virulence of the virus
occurred. The reason for the change in virulence is unknown
and attempts to repeat these experiments by virus passage
have failed to develop additional avirulent strains. The 17D
strain has been widely used as a human vaccine, being safe
and highly effective. It causes a mild, generalized infection in
humans (or other primates) with involvement of lymphoid
tissue and minimal quantities of virus circulating in the blood,
and both the viscerotropism and neurotropism of the parental
Asibi virus are markedly reduced.
We have sequenced the genome of a plaque-purified virus
derived from the 17D-204 vaccine strain of yellow fever (5).
The 17D-204 strain, supplied by the American Type Culture
Collection, had been passed an additional 14 times in chicken
embryo tissue culture, for a total of 234 in vitro passages. To
obtain RNA for cloning and sequencing, the virus was passed
twice in chicken embryo fibroblasts in our laboratory,
plaque-purified in Vero cells, and passed twice in BHK cells;
virus forRNA preparation was then grown in SW-13 cells (5).
Thus, the 17D strain sequenced by us had been passed 240
times in vitro.
We now report the sequence of virtually the entire genome
ofthe Asibi strain of yellow fever and compare the sequences
of the 17D and Asibi strains at both the nucleotide level and
the amino acid level. In addition to defining the changes that
have occurred during 240 serial passages, this work repre-
sents a necessary prelude for studying the biological signif-
icance of these changes as related to the different virulence
of the two strains.
MATERIALS AND METHODS
Asibi Strain Propagation and RNA Isolation. The Asibi
strain of yellow fever virus was obtained from the Yale
Arbovirus Research Unit reference collection as viremic
monkey serum (supplied by R. Shope). This virus was
originally isolated in rhesus monkeys (3) and had undergone
-45 serial monkey passages consistently producing a fatal
illness (6); it is unknown how many of these 45 passages
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correspond to the monkey passages of the laboratory strain
of Asibi used as the starting virus for in vitro passages that led
to 17D. The virulence of this Asibi strain was demonstrated
by inoculation of additional rhesus monkeys, all of which
suffered a lethal infection with yellow fever pathology. Virus
was isolated in LLC-MK2 cell culture by direct inoculation of
viremic plasma from one of these monkeys, and the infec-
tious cell culture fluids were used to infect cultures of Vero
cells. This Vero cell-passaged Asibi strain virus was titered
at 7.8 x 107 plaque-forming units/ml and was used as
inoculum for all subsequent virus production.
Confluent monolayers of Vero cells in 150-cm2 flasks were
infected at a multiplicity of =0.1, and the cultures were
incubated at 360C in Eagle's medium supplemented with 5%
(vol/vol) heated fetal bovine serum and antibiotics. Virus-
containing culture medium was harvested 4-5 days after
infection (depending upon the first evidence of virus induced
cytopathology) and concentrated by polyethylene glycol
precipitation. Virus was purified by density-gradient centrif-
ugation on potassium tartrate/glycerol gradients followed by
rate-zonal centrifugation on linear sucrose gradients, and the
RNA was extracted from NaDodSO4-disrupted virions using
a phenol/cresol/8-hydroxyquinoline/chloroform mixture
(7).
Cloning of Asibi cDNA. A cDNA library from Asibi
genomic RNA was constructed as described (5, 8). Ampicil-
lin-resistant colonies from this library were screened by
colony hybridization using nick-translated restriction frag-
ments derived from the library of 17D yellow fever clones as
probes, as described (9). Colonies with larger inserts (ob-
tained using cDNA size class of 2 kilobases or larger) were
screened with a 5' probe of 2280 base pairs that extends from
the 5' end of 17D yellow fever to the first EcoRI site and with
a 3' probe of 2580 base pairs, which extends from nucleotide
8280 in 17D to the 3' end, or with probes derived from other
regions of the 17D genome. To obtain clones containing the
extreme 3' end of the RNA =4000 clones from the smaller
insert class (derived from Asibi double-stranded cDNA of
0.8-2 kilobases long) were screened with a fragment derived
from the extreme 3' end of 17D. This fragment, 150 nucleo-
tides long, extends from the Xba I site at nucleotide 10,708 to
the 3' end of 17D yellow fever. We found three positive
clones with this probe, two of which were identical. One of
these clones had an unusual structure and probably arose by
self-priming; it was used to obtain the Asibi sequence through
to the 3'-terminal nucleotide.
Sequence Analysis of Asibi cDNA. Plasmid DNA from
selected Asibi clones was sequenced using the chemical
method (10, 11) as described (12).
RESULTS
Sequence of Asibi Yellow Fever. The sequencing strategy
used to obtain the nucleotide sequence of Asibi yellow fever
is diagramed in Fig. 1. The sequence obtained was complete-
ly overlapped and was determined for at least two indepen-
dent clones throughout virtually the entire genome. This
allowed the detection of heterogeneity in the cloned cDNA
population (either due to heterogeneity in the RNA genomes
cloned or due to errors introduced during reverse transcrip-
tion and subsequent cloning). Since the RNA templates that
were used for cloning were not derived from plaque-purified
virus, such clonal differences might be expected, and we
found six nucleotides that differed between two clones. The
sequence obtained totaled 10,848 nucleotides and represents
the entire Asibi genomic RNA sequence with the exception
of the 5'-terminal 14 nucleotides.
Comparison of Nucleotide Sequences of 17D and Asibi
Yellow Fever. All of the nucleotide differences found between


















FIG. 1. Sequencing strategy used to obtain Asibi yellow fever
sequence from cDNA clones. A representation of the yellow fever
genome is shown with the coding region indicated as a box. Below
are shown various cDNA clones drawn to scale. The regions of each
clone sequenced are indicated. All sequencing was 3' to 5' on the
cDNA, and the direction of the arrow indicates whether the plus
strand (4-) or the complementary minus strand (-a) was sequenced.
Clones 3 and 5 start with the 15th and 17th nucleotide, respectively,
from the 5' end of the yellow fever genome. The 3'-terminal 111
nucleotides were present in only one clone, 3'-1, whose structure is
complex and which probably arose by self-priming. In all other
regions at least two independent clones were sequenced.
differences found among the Asibi clones are also presented.
A total of 68 nucleotide differences were found between the
two strains that had been fixed and an additional 6 nucleo-
tides that differed in two different clones of Asibi yellow
fever. In each clonal difference detected, one of the nucle-
otides found at a given position was the same as that found
in 17D yellow fever. The sequence of 17D yellow fever that
has been reported is a consensus sequence derived from
sequencing more than one clone throughout the entire region
(5). With a total of 68 changes (0.63% of the genome) there
was an average of about 0.27 change fixed per passage.
Assuming an effective multiplication of 210 at each passage,
this would represent 2 x 10-6 change fixed per nucleotide per
generation. Changes presumably occur more frequently than
this but do not survive selection pressure during continued
passage.
The nucleotide changes are summarized as to transitions
and transversions in Fig. 3. Transitions are five times more
common than transversions, as expected if most of the
changes occur by mispairing during RNA replication.
Nucleotide changes are scattered throughout the genome
but occurred more frequently in the envelope protein region
(1.0% nucleotide sequence difference), in the ns2a region
(1.6% difference), in the ns2b region (1.0% difference), and in
the 3'-noncoding region (1.2% difference) (Fig. 4). Changes in
the untranslated region may be more frequent because of a
relative lack of selective pressure against changes that occur
in these regions, although it is ofinterest that no changes were
found in the 5'-untranslated region. Within the coding region,
selection against deleterious changes in protein sequence
would be expected, and it is notable that approximately half
of the nucleotide changes (36 of 68 changes) do not result in
a change in a coding assignment. Outside the envelope
protein region and the ns2a regions, in which a dispropor-
tionate number of the nucleotide changes lead to coding
changes, 32 of47 nucleotide changes do not result in an amino
acid substitution.
Changes in Amino Acid Sequence. Amino acid differences
between 17D and Asibi yellow fever are given in Fig. 2 and
summarized in Fig. 4. Overall, there are 32 amino acid
changes (0.94% difference) between the two strains and an
additional three clonal differences in the Asibi strain. Thus,
there has been an average of 0.12 change fixed per passage,
or 4 x 10-6 change per amino acid per generation. As is clear
from Fig. 4, these changes are not randomly distributed.
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FIG. 2. Summary of differences between Asibi
yellow fever and 17D yellow fever. The changes are
grouped by nucleotide number into the various
regions of the genome. Nucleotide number (No) is
from the 5' terminus of 17D. To the right is shown
the nucleotide (NT) in the 17D genome followed by
the nucleotide in the Asibi genome. Where clonal
differences were found in Asibi yellow fever, both
nucleotides as well as both amino acids if appro-
priate are shown. If the nucleotide change results in
an amino acid substitution, the amino acid (AA) in
17D is shown, followed by the amino acid in Asibi.
Note that in every case of clonal differences in the
Asibi strain, one of the nucleotides is the same as
that found in 17D strain.
Proteins E, ns2a, and ns2b exhibit a disproportionately high
rate of change, 2.4% for E, 3% for ns2a, and 2.3% for ns2b.
Only 13 changes, or less than half of the total changes found
between Asibi and 17D, are found in other regions, an amino
acid sequence divergence of only 0.5%.
The function of the various nonstructural proteins in virus
replication is unknown. However, NS3 and NS5 probably
form components of the viral replicase responsible for rep-
licating RNA. If these proteins do possess enzymatic func-
tions, then amino acid changes might be expected to be
deleterious and selected against during continued passage. It
is of note that most of the changes found in NS5 occur near
the ends of the molecule, with only one change occurring
within the central 75% of the protein. It is unknown whether
NS1 has enzymatic activity, but it has been postulated that
since it is a glycoprotein, it may be involved in virus
assembly. The fact that amino acid substitutions in NS1 are
rare, as was the case for NS3 and NS5, suggests that
whatever role it plays in virus replication, it requires a precise
amino acid sequence for that function. NS1, NS3, and NS5
demonstrate a high degree of conservation among different
flaviviruses (13).
The small polypeptides ns2a, ns2b, ns4a, and ns4b are
hydrophobic in nature and are not highly conserved among
flaviviruses (13). Their hydrophobicity profiles are remark-
ably conserved, however, suggesting that as long as the
hydrophobicity profile is unchanged, a large number ofamino
acid substitutions can be accommodated without affecting
the normal function of these proteins. The high frequency of
change observed in the ns2 region may simply be a reflection
of this; many ofthe changes that arise may not affect function
ASIBI 17D No ASIBI 17D No ASIBI 17D No
G A 11 G C 0 C G 1
A G 17 G U 1 C A 2
C U 20 A C 4 U G 3
U C 14 A U 1 U A 0
Pu Py 6 Py Pu 6
Transition 62
Transversion 12
FIG. 3. Transitions and transversions that have occurred during
passage of 17D strain.
and are, therefore, not selected against. The amino acid
changes found in the ns2 region (Fig. 2) would have only
marginal effects upon the hydrophobicity profile.
Amino Acid Changes Within the Structural Protein Region.
No changes were found in the capsid protein, and only one
change was found in prM (this change occurs within M).
There are, however, a large number of changes in the
envelope protein (Figs. 2 and 4). Furthermore, 15 nucleotide
changes in the envelope gene have led to 12 amino acid
substitutions (in contrast to the rest of the coding region
where 53 nucleotide changes lead to 20 amino acid substitu-
tions), suggesting that in the E protein, some of the amino
acid substitutions may have been positively selected for
during passage, rather than simply being neutral in effect.
Although it is impossible to predict the effect ofany particular
amino acid alteration without detailed knowledge of the
three-dimensional structure and function of the protein, five
nonconservative amino acid substitutions are likely candi-
dates to significantly alter envelope protein structure and
function. These are Gly-52 to Arg, Thr-173 to Ile, Lys-200 to
Thr, Pro-320 to Ser, Thr-380 to Arg, and Pro-390 to His. It is
of note that the last two of these changes occur within a
conserved domain of the E protein. The E protein sequences
from flaviviruses representing the three serological sub-
TOTAL CHANGE % CHANGE
FEGKDN NT/AA NT/M NT/M
5'Noncoding 118 / - 0/ - 0 /
Capsid 363 / 121 2 / 0 0.55%/ 0
prM (-M) 267/ 89 0/ 0 0 / 0
M 225 / 75 2 / 1 0.89%/1.89%
Envelope 1479 / 493 15 /12 1.01%/2.43%
NS1 1227 / 409 5 / 2 0.41%/0.49%
ns2a 501 / 167 6/ 5 1.20%/2.99%
ns2b 390/ 130 4/ 2 1.03%/2.31%
NS3 1869 / 623 9 / 2 0.48% / 0.32%
ns4a 861 / 287 6 / 3 0.70% / 0.78%
ns4b 336 / 112 2 / 1 0.60%/0.89%
NS5 2715 / 905 11 / 4 0.40%/0.44%
3'Noncoding 511 / - 6/ - 1.17% /
TOTAL 10862/ 3411 68/32 0.63% / 0.97%
FIG. 4. Summary of the differences between Asibi and 17D
strains at the nucleotide and the amino acid levels. The number of
changes and the percent change at both nucleotide and amino acid
levels are shown for various regions of the genome.
No NT AA No NT MA No NT MA
Capsid 304 A G 3817 G GA 6448 U G
370 C U 3860 G A V M 6529 C U
3915 U UA ns4a 6758 G A V
ns2a 4007 G A A T 6829 C U
M 854 U C F L 4013 U C F L 6876 C U A V
883 G A 4022 G A A T 7171 G A M I
4054 U C
4056 U C F S ns4b 7571 A C
1127 A G R G 7580 C U H Y
1140 U C V A
1482 U C V A 7642 C U
1491 U C T 4289 C A L I 7701 G A R Q
1572 C A T K ns2b 4387 G A 7945 U C
1750 U C 4505 C A L I 8008 C U
1819 U C 4507 C U 8629 U C
Envelope 1870 A G M NS5 9605 G A D N
1887 U C F S 10075 G G,U M M,l
1946 U C S P 10142 A G K E
1965 G A R K 10243 A G
2112 G C R T 4612 C U 10285 C U
2142 A C H P 4864 G GA 10312 G A
2219 A G T A 4873 G U 10316 U U,C S S,P
2356 U C 5131 GGU M M, 10338 U C L P
5153 G A V
NS3 5194 C U 10367 C U
2687 U C F L 5431 U C 3'Non- 10418 C U
2704 G A 5473 U C coding 10454 G A
NS1 3274 A G 5641 A G 10550 C U
3371 G A V I 6013 U C 10800 A G
3613 A G 6023 A G N D 10847 C A
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groups of the mosquito-borne flaviviruses are aligned in Fig.
5; the domain from Pro-369 to Gly-448 shows a high degree
of conservation among flaviviruses. In this region there are
the following three amino acid changes between Asibi and
17D: Thr-380 to Arg, Pro-390 to His, and Ala-416 to Thr. It
is remarkable that in all three cases, 17D changes resulted in
the same amino acid as in the Murray Valley encephalitis/
West Nile/St. Louis encephalitis subgroup offlaviviruses. In
one case the amino acid is also present in dengue-2 virus
(Thr-416), and in a second case (His-390) there is also an
aromatic amino acid (phenylalanine) at the equivalent posi-
tion in dengue-2 virus. It seems unlikely, therefore, that these
alterations in the yellow fever E protein sequence are due to
random events, and it is tempting to speculate that these
substitutions alter receptor affinities. In the Murray Valley
encephalitis subgroup, birds are an important natural host,
and 17D was selected for efficient multiplication in chicken
cells. It should also be kept in mind that only a limited number
of amino acid substitutions might be tolerated.
The 3'-Untranslated Region. Of the six nucleotide changes
found in the 3'-untranslated region, two occur within the
predicted secondary structure at the 3' end of the RNA. One
of these would result in an extra A-U base pair in the
3'-terminal 88 nucleotides, while the second results in the loss
of an A-U base pair; thus these two changes should have only
a minor effect on the stability of the proposed secondary
structure.
There are three repeated-sequence elements in the 3'-
untranslated region that are 42 nucleotides long, each of
which differs from the others by 4 or 5 nucleotides. These
repeats are shown for Asibi RNA in Fig. 6. Note that within
this repeat, there are 16 contiguous nucleotides that are
repeated identically. In 17D RNA there has been an adeno-
sine to guanosine transition at nucleotide 10,454 that results
in a mismatch within one copy of this perfect repeat. The
significance of this change is unknown.
DISCUSSION
The 17D strain of yellow fever virus is one of the safest and
most effective live virus vaccines ever developed, especially
after stabilization of seed lots (for a study ofthe different seed
Proc. Natl. Acad. Sci. USA 84 (1987)
lots see ref. 17). In this report we detail the differences in
nucleotide and amino acid sequence between this vaccine
strain and the parental Asibi isolate from which it was
derived. The change or changes responsible for the altered
virulence or attenuation of 17D cannot be determined at the
current time. Indeed, the situation is complicated by the fact
that the 17D vaccine contains a mixture of variants that differ
in a number of biological properties (17, 18). It is unclear
which of these variants was sequenced to obtain the 17D
sequence, since the vaccine strain was plaque-purified before
amplification and sequencing. It is unknown if this mixture of
variants is important for the vaccine properties of the 17D
strain; however, reversion to virulence has never been
documented. It is known that a change occurred in the
virulence of yellow fever between the 89th and 114th passage;
that this change, once it occurred, was stable; and that
comparable changes were not obtained when the passage
history of the 17D strain was repeated. The Asibi strain
sequenced was not plaque purified and a number of clonal
differences were found.
Attenuation of a virus by propagation in tissue culture
presumably results from selection for variants better adapted
for replication in tissue culture and, conversely, less-well
adapted for replication in their natural hosts, although accu-
mulation and fixation of nonselected mutations may also be
important. In particular, variants might be selected that bind
more readily to receptors on cultured chicken cells, leading
to more rapid attachment and penetration. Such an alteration
in receptor binding could, as a consequence, lead to less-
efficient binding to receptors found in hepatocytes or neurons
in primates, and thus to an alteration in tissue tropism and
reduction in virulence. The large number of changes found in
the envelope protein is consistent with such an hypothesis.
Changes elsewhere in the genome may also be important,
however, particularly if they affect the efficiency of virus
replication. Because of the stability of the vaccine strain, it
is likely that more than one change is important for its
avirulence. If it becomes possible to rescue infectious virus
from a cloned cDNA copy of yellow fever, as has been done
for several RNA viruses (19-21), it will be possible to test the
effect of the individual changes found on the virulence of the
virus. Such an approach has been used with the Sabin and
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FIG. 5. Envelope protein se-
quences of five flaviviruses. The
aligned amino acid sequence of
five flavivirus E proteins are
shown in the single-letter amino
acid code. Dots indicate that the
amino acid is the same as in Asibi
yellow fever strain. Murray Valley
encephalitis (MVE) (14), West
Nile (WN) (15), and St. Louis
encephalitis (SLE) (16) viruses be-
long to a separate serological sub-
group of mosquito-borne flavivi-
ruses. Dengue 2 (DEN 2) virus is a
member of a third subgroup (Y. S.
Hahn, R. Galler, J.M.D., J.H.S.,
and E. G. Strauss, unpublished
data). Cysteine residues are shad-
ed, and potential carbohydrate ad-
dition sites are boxed.
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10372 AUAACCGGGAUACAAACCACGGGUGGAGAACCGGACUCCCCACA 10415
10420 GA.......U C. G U 10463
10476 GA A....U....A.. A 10519
FIG. 6. Repeated sequences in the 31-untranslated region. The
sequences ofthree repeats in the 3'-untranslated region ofAsibiRNA
are aligned. Nucleotide 10,454 is a guanosine in the 17D strain, which
introduces a mismatch in a 16-nucleotide perfect repeat.
Mahoney strains of poliovirus type I, with the finding that
several changes within the genome are involved in the change
in virulence between the two strains (22, 23).
Studies by Schlesinger et al. (24) have shown that mono-
clonal antibodies against the envelope protein of 17D yellow
fever are often able to discriminate between 17D and Asibi
yellow fever. Interestingly, some of these antibodies neutral-
ize Asibi virus but not 17D virus. This suggests that changes
in the E proteins are important for determining the structure
of E and/or are found in regions important for antibody
binding. These authors also found that E proteins of 17D were
present in both glycosylated and nonglycosylated forms,
whereas Asibi E protein was present in only one form
(presumably nonglycosylated from its mobility relative to
that of 17D E protein, since we show here that the two
proteins are identical in size). No change in the single
potential glycosylation site was found between 17D and
Asibi, although the change of Phe-305 to Ser is found just
upstream of this site. Presumably this change, or other
changes upstream that affect the folding of the proteins, leads
to changes in accessibility of the site to the glycosylation
enzymes.
This study is also of interest because it represents a
detailed study of differences that have arisen during 240
passages in which the passage history is known with some
clarity. RNA replicases lack proofreading activity and the
error frequency of these enzymes is estimated to be on the
order ofabout 10-4 per nucleotide per generation, based upon
theoretical considerations of the free energy of an A-U or G-C
base pair, or upon measured mutation frequencies in a
number of virus systems (25, 26). However, measurements in
other systems have yielded lower estimates of mutation
frequency. Parvin et al. (27) found a substitution frequency
in the NS gene of influenza of 4 x 10-6 substitution per
nucleotide per generation and <5 x 10-7 substitution per
generation in the poliovirus VP1 gene. We report here that
yellow fever underwent 2 x 10-6 substitution per nucleotide
per generation during passage ofthe 17D strain. The difficulty
in relating the various mutation rates observed comes in
estimating the fraction of nucleotide substitutions that are
capable of survival under the conditions used, which will
differ with the protein domain under consideration (some
domains or even entire proteins tolerate changes more than
others) and with the method of selection [simple ability to
persist in a population and form a plaque, as was used by
Parvin et al. (27), or ability to compete head to head with
other viruses in the population, as was the case with yellow
fever 17D]. Domingo et al. (28) have shown with bacterio-
phage Qf3 that in direct competition, the RNA population
consists of an average nucleotide sequence that is maintained
during passage, but in which variants arise at high frequency
that are subsequently selected against during continued
passage. Since many nucleotide changes studied were almost
certainly silent changes, the RNA secondary structure of Q13
appears to be important for rapid growth and even silent
changes may be selected against, a situation that may well
prevail with other RNA viruses and especially with plus-
strand RNA viruses. Thus it is unclear whether even the
incidence of silent change can be used to assay the inherent
mistake frequencies of the viral RNA polymerases. In the
case of 17D yellow fever, those alterations that have been
fixed presumably represent mutations that are truly neutral
(or possibly fixed during plaque purification) as well as
positive changes that lead to more efficient growth in tissue
culture.
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